Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study

Abstract

Background

Early intervention with an effective disease-modifying drug (DMD) offers the best chance of limiting the inflammatory process that contributes to irreversible axonal damage correlating with disability in multiple sclerosis (MS). It is equally important to ascertain fairly quickly whether patients are responding positively to the choice of therapy to allow time for either a treatment modification or a switch in treatment, a process we termed “treatment optimization”. Various treatment optimization recommendations (TOR) have been proposed to help decide when a patient taking an MS DMD might be showing a sub-optimal response. We have applied the clinical scheme proposed by the Canadian TOR to the patients involved in the Prevention of Relapses and disability by Interferon Subcutaneously in MS 4-year (PRISMS-4) study, who received interferon β-1a treatment for 4 years, with the TOR applied retrospectively at year 1.

Objective

The aim of this investigation was to examine whether these TOR were able to predict which patients would go on to develop disease breakthrough (defined as any relapses or disease progression), indicative of a sub-optimal response over the ensuing 3 years of study and therefore might have benefited from a change in treatment.

Results

We found 39% of patients receiving therapy experienced either a medium or high level of concern of breakthrough after a year of treatment, and 89% of these patients went on to develop further breakthrough over years 2–4. Although 67% of the 61% of patients having no or low-level concern after a year of treatment also experienced further disease breakthrough, it was significantly less than the medium or high group.

Conclusion

This study shows that the Canadian TOR may be an important tool for early treatment optimization.

Keywords

disease-modifying drugs early treatment multiple sclerosis treatment optimization

Get full access to this article

View all access options for this article.

References

1 Ferguson B Matyszak MK Esiri MM Perry VH . Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393–399.

2 Trapp BD Peterson J Ransohoff RM Rudick R Mork S Bo L . Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

3 Matthews PM De Stefano N Narayanan S . Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 1998; 18: 327–336.

4 De Stefano N Narayanan S Francis GS . Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65–70.

5 Goodin DS Frohman EM Garmany GP . Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology 2002; 58: 169–178.

6 Izquierdo G . Preventive treatment of multiple sclerosis. Rules for treatment with immunomodulators. Rev Neurol 2002; 35: 1094–1099.

7 Jakab G . Guidelines for comprehensive therapy in multiple sclerosis. Orv Hetil 2004; 145: 1629–1631.

8 Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA) . Guideline for the use of beta-interferons in patients with multiple sclerosis – a South African proposal. S Afr Med J 2004; 94: 917–921.

9 Academia Brasileira de Neurologia . Departamento Científico de Neuroimunologia. Guidelines for the treatment of multiple sclerosis with immunomodulatory drugs. Arq Neuropsiquiatr 2005; 63: 892–895.

10.

10 Ziemssen T Wilhelm H Ziemssen F . Multiple sclerosis. An update with practical guidelines for ophthalmologists. Ophthalmologe 2006; 103: 621–641.

11.

11 Bashir K Buchwald L Coyle PK . Optimizing immunomodulatory therapy for MS patients. Int J MS Care 2002; 4: 3–7.

12.

12 Oger J Freedman M . Consensus statement of the Canadian MS clinics network on: the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999; 26: 274–275.

13.

13 Freedman MS Blumhardt LD Brochet B . Paris Workshop Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002; 8: 19–23.

14.

14 Rieckmann P . Escalating immunomodulatory therapy of multiple sclerosis: update (September 2006). Nervenarzt 2006; 77: 1506–1518.

15.

15 Freedman MS Patry DG Grand'Maison F Myles ML Paty DW Selchen DH . Working Group. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004; 31: 157–168.

16.

16 PRISMS . (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

17.

17 PRISMS . (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing, MS. Neurology 2001; 56: 1628–1636.

18.

18 Kappos L Traboulsee A Constantinescu C . Long-term subcutaneous interferon beta-1a therapy in patients with relapsing–remitting, MS. Neurology 2006; 67: 944–953.

19.

19 Tomassini V Paolillo A Russo P . Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006; 253: 287–293.

20.

20 Simon JH Li D Traboulsee A . Standardized MR imaging protocol for multiple sclerosis: consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006; 27: 455–461.

21.

21 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

22.

22 Polman CH Reingold SC Edan G . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840–846.

23.

23 Mikol D Barkhof F Chang P . REGARD Study Group. The REGARD trial: a randomised assesssor-blinded trial comparing interferon beta-1a and glatiramer acetate in relapsing–remitting multiple sclerosis. Mult Scler 2007; 13(Suppl. 2): 119.

24.

24 Coles A . Efficacy of alemtuzumab in treatment-naive relapsing–remitting multiple sclerosis: analysis after two years of study CAMMS223. Abstract S12.004. In: Boston, Massachusetts, USA: American Academy of Neurology 2007.

25.

25 Sellebjerg F Barnes D Filippini G . EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J Neurol 2005; 12: 939–946.

26.

26 Zaffaroni M . Treatment optimisation in multiple sclerosis. Neurol Sci 2005; 26(Suppl. 4): S187–S192.

27.

27 Rio J Nos C Tintore M . Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 2002; 52: 400–406.

28.

28 Freedman MS . on behalf of the PRISMS study group. Utility of treatment optimisation recommendations applied to clinical trial data: Results from the PRISMS study. Poster presented at ECTRIMS 2004. p. 611.

29.

29 Ruiz Pena JL Duque P Izquierdo G . Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria. BMC Neurol 2008; 8: 3.

30.

30 Karussis D Biermann LD Bohlega S . The International Working Group for Treatment Optimization in MS. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006; 13: 61–71.

31.

31 Frohman E Phillips T Kokel K . Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002; 8: 227–236.